Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 5.3% over the past four weeks to close the last trading session at $6.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.33 indicates a potential upside of 297%. The average comprises three short-term price targets ranging from a low of $18.00 to a high of $30.00, with a standard deviation of $6.43. While the lowest est ...